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Abstract
Alternative splicing of estrogen receptor β (ERβ) yields five isoforms, but their functions remain elusive. ERβ isoform 5
(ERβ5) has been positively correlated with better prognosis and longer survival of patients with breast cancer (BCa)
in various clinical studies. In this study, we investigated the inhibitory role of ERβ5 in BCa cells. Although ERβ5 does
not reduce proliferation of BCa cell lines MCF-7 and MDA-MB-231, its ectopic expression significantly decreases
their survival by sensitizing them to doxorubicin- or cisplatin-induced apoptosis through the intrinsic apoptotic
pathway. Moreover, we discovered Bcl2L12, which belongs to the Bcl-2 family regulating apoptosis, to be a specific
interacting partner of ERβ5, but not ERβ1 or ERα, in an estradiol-independent manner. Knockdown of Bcl2L12
enhanced doxorubicin- or cisplatin-induced apoptosis, and this process was further promoted by ectopic expression
of ERβ5. Whereas Bcl2L12 was previously shown to inhibit apoptosis through binding to caspase 7, such interaction
is reduced in the presence of ERβ5, suggesting a mechanism by which ERβ5 sensitizes cells to apoptosis. In conclu-
sion, ERβ5 interacts with Bcl2L12 and functions in a novel estrogen-independent molecular pathway that promotes
chemotherapeutic agent–induced in vitro apoptosis of BCa cell lines.
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Introduction
Breast cancer (BCa) is the leading cause of cancer-related death in
women worldwide. Estrogen receptors (ERs) are one of the most
important biomarkers for the prediction of prognosis and response
to therapy among patients with BCa [1]. Hormonal therapy through
estrogen depletion or with selective ER modulators is widely used
to block the action of estrogen on its receptors and to induce cell
death. Nonetheless, this therapy can be applied only in patients with
estrogen-sensitive BCa [2]. Even worse, some patients with advanced
BCa eventually are unresponsive to selective ER modulators [3,4] and
require chemotherapy as second-line treatment, with its severe adverse
effects, especially at high dosage [5,6].
In contrast to ERα, which has a proliferative action in BCa, ERβ has
been found during the last few years to be protective. Although ERα is
generally known to promote BCa tumorigenesis [7,8], ERβ was found
to antagonize ERα by negating ERα activity [9]. A decrease in ERβ
expression during the progression of BCa suggests that ERβ is anti-
proliferative and suppresses carcinogenesis [10–12]. ERβ also can
inhibit the survival of BCa cells by promoting apoptosis and en-
hancing the efficacy of apoptotic chemotherapeutic agents [13–16].
For example, ERβ expression triggers the activation of p53 through
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phosphorylation and enhances apoptosis [17,18]. A genome-wide
study showed that ERβ downregulates antiapoptotic factors in either
the absence or presence of estradiol (E2) [19]. Its expression also sen-
sitizes BCa cells to doxorubicin and cisplatin [20,21], an effect indepen-
dent of ligand. Moreover, various studies showed that ERβ agonists
confer resistance of BCa cells to chemotherapeutic agents [22–24],
suggesting that ERβ may enhance the chemosensitivity of cells in a
ligand-independent manner.
Alternative splicing of ESR2 gene produces ERβ1 (or wild-type
ERβ) and its four isoforms, including ERβ isoform 2 (ERβ2) to
ERβ5, which possess unique amino acid sequences at their carboxyl
(C) terminus [9]. Although ∼90% of their sequences are identical
with that of ERβ1, their binding to estrogen is either weak (ERβ4
and ERβ5) or absent (ERβ2) [25]. Our previous study demonstrated
that the activation function 2 (AF-2) domain at C termini is respon-
sible for their estrogen independence [25]. Therefore, these isoforms
are considered to be transcriptionally inactive but capable of modulat-
ing ERβ1- or ERα-mediated transcription when heterodimerized with
them [26,27]. ERβ5 expression, similar to that of ERβ1, was shown
to be protective in patients with BCa [28,29] and may inhibit tumor
growth [30]. Other studies reported a positive association of ERβ5
expression with a longer relapse-free survival (RFS) [31] and a signif-
icant correlation of its nuclear expression with overall survival (OS)
[29], suggesting that ERβ5 expression may be a powerful prognostic
marker for BCa. Thus, we are interested in clarifying its functions
in BCa.
Our current study revealed the role and molecular mechanism of
ERβ5 in apoptosis of BCa cells. To investigate functions of ERβ5, we
performed yeast two-hybrid screening and isolated Bcl2L12, which is
a Bcl-2 family member, and found that Bcl2L12 interacts specifically
with ERβ5 but not with other ER subtypes. Bcl2L12 has opposing
roles in apoptosis in different cancers [32,33]. Therefore, we also de-
termined the effect of Bcl2L12 expression on BCa cell lines treated
with apoptosis-inducing drugs. Moreover, we investigated the relation-
ship between ERβ5-mediated sensitization of cells to apoptosis and
the interaction of ERβ5 with Bcl2L12 and found that ERβ5 confers
sensitivity of BCa cells to apoptosis-inducing chemotherapeutic agents
through direct interaction with Bcl2L12.
Materials and Methods
Cell Cultures and Reagents
MCF-7, MDA-MB-231, 293T, and 293FT cells were purchased
from American Type Culture Collection (ATCC, Manassas, VA) and
maintained according to the manufacturer’s protocols. Stably expressed
cell lines were also supplemented with blasticidin (10 μg/ml; Life
Technologies, Carlsbad, CA).
Plasmids were transfected into 293T or 293FT cells by Lipofectamine
2000 (Life Technologies). DharmaFECT 1 was used as the small
interfering RNA (siRNA) transfection reagent (Thermo Scientific
Dharmacon, Florence, KY) for MCF-7 and MDA-MB-231. Procedures
of transfection were those recommended by the manufacturer. The
chemotherapeutic agents doxorubicin hydrochloride and cisplatin [cis-
diamminedichloroplatinum(II)] were purchased from Sigma-Aldrich
(St Louis, MO).
Plasmids and siRNAs
Full-length ERβ1, ERβ5, ERα, and Bcl2L12 were cloned into
pcDNA-HisMax (Life Technologies). The siRNA oligonucleotides
specific to Bcl2L12, siL12-1 (AAGCUGGUCCGCCUGUCCU),
and siL12-2 (UGGUGGAGCUGUUCUGUAG) were used for the
knockdown of Bcl2L12 (Thermo Scientific Dharmacon). The
sequences were based on the published data of Stegh et al. [34].
ON-TARGETplus nontargeting siRNA (siNT) was used as the
negative control (Thermo Scientific Dharmacon).
Antibodies
Rabbit polyclonal anti-ERβ (H-150) and goat polyclonal anti–
caspase 7 (N-17) were purchased from Santa Cruz Biotechnology
(Dallas, TX). Mouse monoclonal anti-His (THE His) was purchased
from GenScript (Piscataway, NJ). Mouse monoclonal anti-ERβ (14C8)
was purchased from Abcam (Cambridge, MA). Rabbit anticleaved poly
(ADP-ribose) polymerase (PARP), anticleaved caspase 3, anticleaved
caspase 7, anticleaved caspase 8, and anti–caspase 9 were purchased
from Cell Signaling Technology (Danvers, MA). EZview anti-HA
affinity gel was purchased from Sigma-Aldrich. Two custom rabbit poly-
clonal anti-Bcl2L12 (anti–L12-1 and anti–L12-2) were kindly provided
by Dr Alexander H. Stegh at Northwestern University (Evanston, IL).
All control IgGs were purchased from Santa Cruz Biotechnology.
Construction of ERβ5 Stably Expressed Cell Lines
Procedures of constructing stably expressed cell lines have been de-
scribed previously [35]. In brief, full-length ERβ5 or LacZ (negative
control), respectively, was subcloned into pLenti6 lentiviral vector by
Multisite Gateway Cloning (Life Technologies) and then transfected
into 293FT cells for production of lentivirus. The titer of each lenti-
virus was measured, and the multiplicity of the infection of MCF-7
and MDA-MB-231 cells was determined. Lentivirus-infected MCF-7
and MDA-MB-231 cells were selected with blasticidin (10 μg/ml) for
3 weeks. Stable expression of ERβ5 or LacZ was confirmed by quan-
titative reverse transcription–polymerase chain reaction (RT-PCR),
Western blot analysis, and β-galactosidase assay.
RNA Extraction and Quantitative RT-PCR
Total RNA was extracted with TRIzol reagent (Life Technologies),
and cDNA was synthesized with SMARTMMLV reverse transcriptase
with poly d(T) primer (Promega, Fitchburg, WI). All the procedures
followed the manufacturer’s instructions. Quantitative RT-PCR re-
actions were performed with ABI7900 real-time PCR system (Life
Technologies). Intron-spanning primers of ERβ5 (forward—5′-
CGGAAGCTGGCTCACTTGCT-3′ and reverse—5′-CTTCACC-
CTCCGTGGAGCAC-3′) and Bcl2L12 (forward—5′-CCTGTTCC-
AACTCCACCTAGAA-3′ and reverse—5′-GACTCAGAGGGGGC-
TGCT-3′) were used. The primers of Bcl2L12 were designed spe-
cifically for amplification of the sequence in the wild type of Bcl2L12
but not in the truncated form, Bcl2L12A.
3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-
(4-Sulfophenyl)-2H-Tetrazolium Cell Proliferation Assay
MCF-7 andMDA-MB-231 were seeded in 96-well plates at 3 × 103.
After 24 hours, the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was performed
to normalize the number of cells in each well. The CellTiter 96 AQueous
Non-Radioactive Cell Proliferation Assay (Promega), following the
manufacturer’s protocol, was used for the experiment. The reading was
taken at 24, 72, and 120 hours for cell proliferation experiments or
after 24 and 48 hours of drug treatments for cell viability experiments.
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Treatment with Apoptosis-Inducing Chemotherapeutic Agents
Cells were seeded on 6-well plates at 3.3 × 105 (MCF-7) or 1.8 ×
105 (MDA-MB-231). They were stably transfected with expression
plasmids and/or transiently transfected with siRNAs as described.
Medium was added with or without doxorubicin or cisplatin at dif-
ferent concentrations after 24 hours. The adherent and nonadherent
cells were harvested and lysed with M-PER lysis buffer (Thermo
Scientific Pierce, Florence, KY) containing complete EDTA-free
protease inhibitor cocktail (Calbiochem, Billerica, MA). Equal amounts
of total protein lysates were used in Western blot analysis. Different
antibodies to apoptotic markers (cleaved PARP, cleaved caspase 3,
cleaved caspase 7, cleaved caspase 8, and cleaved caspase 9) and other
relevant antibodies were used as stated. Target proteins were detected
with IRDye secondary antibody, and signals were obtained with the
Odyssey Infrared Imaging System (Li-Cor Biosciences, St Lincoln,
NE). Relative band intensities were measured by ImageJ analysis
(National Center for Biotechnology Information, Bethesda, MD).
Staining with Annexin V and 7-Aminoactinomycin D
MCF-7 and MDA-MB-231 cells were seeded on 12-well plates
at 2 × 105 (MCF-7) or 1 × 105 (MDA-MB-231). The medium was
added, with doxorubicin or cisplatin at different concentrations, for
18 hours. The adherent and nonadherent cells were collected. Cells
were washed with phosphate-buffered saline, resuspended in the bind-
ing buffer, and then incubated with annexin V–Alexa Fluor 488 (Life
Technologies) and 7-aminoactinomycin D (7-AAD; BD Biosciences,
San Jose, CA) for 10 minutes in the dark. FACS analysis was performed
with FACSCalibur (Becton Dickinson, Franklin Lakes, NJ). Data
analysis was done by CellQuest Pro version 5.2 (BD Biosciences).
Yeast Two-Hybrid Screening
Human prostate MATCHMAKER cDNA library (Clontech Labo-
ratories, Mountain View, CA) was used as prey library for screening.
C-terminal ERβ was cloned into the bait vector pGBKT7 (Clontech
Laboratories). The screening procedures followed the manufacturer’s
protocol. In brief, the bait vector and prey library were transformed
to yeast strain AH109 and Y187, respectively. Yeast mating was
performed at 30°C at a low shaking speed. Clones were selected on
quadruple nutrient dropout agar (QDO; Clontech, Mountain View,
CA; SD/−Ade-His-Leu-Trp). Positive clones were isolated, and the pres-
ence of coding sequences was confirmed by PCR screening. The inter-
action was confirmed by cotransforming bait and prey plasmids into
yeast strain Y187 using the polyethylene glycol–lithium acetate method
of the Yeastmaker Yeast Transformation System (Clontech Laborato-
ries). Full-length ERβ1, ERβ5, and ERα were subcloned into pGBKT7
vector as baits in the cotransformation assay. Transformed cells were
grown on QDO agar with X-α-galactosidase for 4 days until blue yeast
colonies appeared.
In Vitro Coimmunoprecipitation
The yeast plasmid containing the partial sequence of Bcl2L12 was
extracted. T7 promoter and hemagglutinin (HA) tag were added
to the N terminus of the coding sequence by the PCR reaction.
Plasmids of full-length ERβ1, ERβ5, and ERα and PCR products con-
taining Bcl2L12 were respectively translated in vitro by the TNT
T7-reticulocyte system (Promega) labeled with EasyTag EXPRESS
35S Protein Labeling Mix (PerkinElmer, Hebron, KY). In vitro–
translated bait and prey proteins were incubated together in the
absence or presence of E2 at 4°C for 1 hour. Lysates were then immu-
noprecipitated with 20 μl anti-HA affinity gel (Sigma-Aldrich) at 4°C
overnight. The samples were subjected to sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis. Dried gels were exposed to X-ray films
for 72 hours with intensifying screen for signal enhancement (Kodak,
Rochester, NY). The films were scanned with the Odyssey Infrared
Imaging System (Li-Cor Biosciences).
Mammalian Coimmunoprecipitation
The 293T cells were seeded on 60-mm plates at 3 × 106 in charcoal-
stripped serum medium and transfected with different plasmids for
24 hours; the culture medium was added with DMSO (as vehicle
control) or 10 nM E2 as indicated. MCF-7 cells grown in full-serum
medium were used in the coimmunoprecipitation (co-IP) experiment.
Cells were lysed with IP Lysis Buffer (Thermo Scientific Pierce) con-
taining protease inhibitor. One milligram of lysate was immuno-
precipitated with 2 μg of the appropriate antibodies at 4°C overnight
and then with protein G Dynabeads (Life Technologies). Control IgG
was used as the negative control. The samples were subjected to
Western blot analysis. IRDye secondary antibodies were used to detect
protein bands, and the Odyssey Infrared Imaging System (Li-Cor
Biosciences) was used to obtain the signals.
Immunofluorescence Staining
The 293T cells were seeded on round coverslips and transfected
with ERβ5 and Bcl2L12; MCF-7–ERβ5 cells were also seeded on
coverslips without any transfection. Cells were fixed in 10% formalin
at room temperature for 20 minutes and permeabilized with 1%
NP-40. Normal chicken serum (10%) was used for blocking. Mouse
ERβ (14C8) and rabbit Bcl2L12 antibodies (anti–L12-2) were in-
cubated with the cells at room temperature for 1 hour. Different
fluorescent secondary antibodies were then incubated with the
cells for 1 hour in the dark. Cell nuclei were counterstained with
4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Prolong
Gold antifade reagent (Life Technologies) was used for enhancing
signals. The fluorescent images were obtained by an Axiovert 200M
fluorescent microscope equipped with an AxioCam MRm camera
and AxioVision 4.8 software (Carl Zeiss, Oberkochen, Germany).
Statistical Analysis
Student’s t test was used for statistical analysis (GraphPad Software,
La Jolla, CA). All P values were two-sided, and P < .05 was considered
to be statistically significant.
Results
Ectopic Expression of ERβ5 in BCa Cell Lines Does Not
Alter Cell Proliferation
To investigate the underlying mechanisms and functions of ERβ5 in
BCa, we constructed BCa cell lines expressing either ERβ5 or LacZ.
Two BCa cell lines, MCF-7 and MDA-MB-231, were chosen because
of their different ERα and p53 status; MCF-7 is ERα and p53 positive,
whereas MDA-MB-231 is ERα negative and possesses a mutant form
of p53 [36,37]. The mRNA and protein expression were measured
after the construction of ERβ5 stably expressed MCF-7 (Figure 1A)
and MDA-MB-231 (Figure 1B). Unlike the antiproliferative role of
ERβ1 in BCa [38], ectopic expression of ERβ5 did not alter cell prolif-
eration of either cell line (Figure 1, C and D), suggesting that ERβ5
has no significant effect on cell proliferation in BCa cells.
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ERβ5 Functions in the Intrinsic Apoptotic Pathway and
Sensitizes BCa Cell Lines to Doxorubicin-Induced Apoptosis
ERβ5 expression significantly correlates with better RFS and OS of
patients with BCa [29,31]. Although ERβ5 expression does not alter
the proliferation of BCa cells, it may determine cell survival through
other molecular pathways, such as apoptosis. Doxorubicin induces
apoptosis and is a standard chemotherapy for patients with BCa [39],
whereas its high dosage increases the risk of cardiotoxicity and other
adverse effects [40]. To determine whether the presence of ERβ5 can
sensitize cells to doxorubicin treatment, we treated ERβ5 or LacZ stably
expressed MCF-7 (MCF-7–ERβ5/−LacZ) with different concentra-
tions of doxorubicin for 12 hours (data not shown) or 24 hours (Fig-
ure 2A). With doxorubicin treatment, MCF-7–ERβ5 showed an
increase, compared with the LacZ control, in the expression of cleaved
caspase 9 but not cleaved caspase 8, indicating activation of the in-
trinsic pathway. The expression of cleaved PARP and cleaved caspase 7,
which are the late apoptotic markers, also increased (Figure 2A). To
further determine ERβ5-mediated sensitization, we confirmed the
apoptotic status of cells using annexin V/7-AAD FACS analysis. Again,
we found an increase in apoptosis of MCF-7–ERβ5 cells with doxo-
rubicin treatment compared with the LacZ control (Figure 2B). More-
over, after doxorubicin treatment, survival of MCF-7–ERβ5 cells was
significantly lower than that of MCF-7–LacZ, as measured by the
MTS assay (Figure 2C ). Results were similar in ERβ5 or LacZ stably
expressed MDA-MB-231 (MDA-ERβ5/−LacZ; Figure W1, A–C ).
Thus, we infer that ERβ5 sensitizes BCa cells to doxorubicin-induced
apoptosis through an intrinsic apoptotic pathway.
ERβ5 Sensitizes BCa Cell Lines to Cisplatin-Induced Apoptosis
ERβ5 was shown to confer chemosensitivity of BCa cells to
doxorubicin-induced apoptosis. Because cisplatin induces apoptosis
through a mechanism distinct from that with doxorubicin [41,42]
and is effective against triple-negative BCa [43–45], we next exam-
ined whether ERβ5 can improve the efficacy of cisplatin in BCa cells.
Experiments were similar to those done for doxorubicin in BCa cell
lines. MCF-7–ERβ5 showed greater sensitivity to cisplatin treatment
than the LacZ control, as reflected by enhanced activation of PARP,
caspase 9, and caspase 7 (Figure 3A) and a greater percentage of apop-
totic cells in FACS analysis (Figure 3B). Cell survival was significantly
decreased with cisplatin treatment in MCF-7–ERβ5 as measured by
the MTS assay (Figure 3C ). Results were similar in MDA-MB-231
ectopically expressed with ERβ5 (Figure W2, A–C ). These findings,
taken together, indicate that ERβ5 enhances the chemosensitivity of
MCF-7 and MDA-MB-231 to cisplatin-induced apoptosis.
Bcl2L12 Specifically Interacts with ERβ5 in an
E2-Independent Manner
To identify novel ERβ5-mediated molecular pathways, we employed
yeast two-hybrid screening using ERβ as bait to isolate its interacting
partners in a human total cDNA library. We isolated a clone that
encodes amino acids 14 to 273 of human Bcl2L12. To eliminate a
false-positive interaction and to determine whether Bcl2L12 interacts
with other ERs, we performed yeast cotransformation of Bcl2L12 with
full-length ERβ5, ERβ1, or ERα. Bcl2L12 showed a strong interac-
tion with ERβ5 and a weak interaction with ERα but did not interact
with ERβ1 (Figure W3A). The physical binding between the proteins
was further verified by in vitro co-IP. ERβ5 interacted with Bcl2L12
(Figure W3B, lane 2), whereas ERα (Figure W3B, lanes 6 and 7)
and ERβ1 (Figure W3B, lanes 9 and 10) could not be coimmuno-
precipitated with Bcl2L12 in the absence or presence of E2. Next,
we confirmed the interaction in mammalian cells. Full-length se-
quence of Bcl2L12 was cloned from MCF-7. Consistent with the
results in two-hybrid assays and in vitro co-IP, Bcl2L12 was coimmuno-
precipitated with ERβ5 independent of E2 in 293T cells (Figure 4A,
lanes 3 and 5) but not with ERβ1 or ERα (data not shown). The inter-
action was further confirmed in MCF-7–ERβ5 (Figure 4B). More-
over, immunofluorescence staining showed that ERβ5 and Bcl2L12
were localized in the same subcellular compartments. Colocalization
was observed in both nucleus and cytoplasm of 293T (Figure W3C )
and MCF-7–ERβ5 cells (Figure W3D). In conclusion, we deter-
mined that ERβ5, but not ERα or ERβ1, interacts with Bcl2L12 in
an E2-independent manner.
Figure 1. Ectopic expression of ERβ5 in BCa cell lines does not
alter the rate of cell proliferation. (A and B) ThemRNA and protein ex-
pression of ERβ5 were determined in ERβ5 or LacZ stably expressed
MCF-7 (A) and MDA-MB-231 (B) cell lines by quantitative RT–PCR
andWestern blot analysis, respectively. Glyceraldehyde 3-phosphate
dehydrogenase (GADPH) was used as the housekeeping gene in
quantitative RT-PCR, whereas α-tubulin served as the loading control
in Western blot analysis. The cell lines were stably transfected with
either an ERβ5 or LacZ expression plasmid. Results are the average
of two independent experiments. Data are represented as means ±
SD. (C and D) Ectopic expression of ERβ5 does not alter the prolifer-
ation rate of BCa cells. The proliferation rates of MCF-7 (C) andMDA-
MB-231 (D) were measured by MTS assay. Equal numbers of cells
(3 × 103) were seeded on 96-well plates. The data were recorded
after days 1, 3, and 5 and represented as the percentage of cell pro-
liferation relative to LacZ stably expressed cells on day 1. The re-
sults are the average of three independent experiments; each was
performed in triplicate. Data are represented as means ± SD.
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Knockdown of Bcl2L12 Sensitizes BCa Cells to
Doxorubicin and Cisplatin
Bcl2L12 acts as a proapoptotic or antiapoptotic factor in different
cancers [33,46]. To explore the functions of Bcl2L12 in BCa, we used
the gene knockdown approach, because Bcl2L12 is highly expressed
in MCF-7 and MDA-MB-231 (Figure W4A). Moreover, ectopic
expression of ERβ5 did not alter the expression of Bcl2L12 (FigureW4,
B and C). Two Bcl2L12 siRNAs (siL12-1 and siL12-2), validated by
Stegh et al. [34], significantly decreased its mRNA and protein levels
in MCF-7 (Figure W4, D and E ) and MDA-MB-231 (Figure W4,
F and G ). PARP, caspase 9, caspase 7, and caspase 3 were moderately
activated in the absence of apoptotic drugs after knockdown of Bcl2L12
by either siL12-1 (Figure 5B, lanes 4 and 10) or siL12-2 (Figure W5B,
lanes 3 and 7) in MDA-MB-231.
With doxorubicin treatment, depletion of Bcl2L12 by siL12-1 in
MCF-7 increased the activation of PARP, caspase 9, and caspase 7
(Figure 5A, lanes 5 and 11). Although activation of caspase 7 and
caspase 3 was enhanced with similar treatment in MDA-MB-231
(Figure 5B, lanes 5 and 11), cleavage of PARP and caspase 9 was simi-
lar with and without the knockdown by siL12-1 (Figure 5B, lanes 2,
5, 8, and 11). MCF-7 and MDA-MB-231 with ectopic expression of
ERβ5 and knockdown of Bcl2L12 showed the highest expression of
apoptotic markers (Figure 5, A and B, lane 11). The inhibitory effect
of Bcl2L12 on doxorubicin-induced apoptosis was confirmed by its
depletion with the use of its second siRNA, siL12-2 (Figure W5, A
and B, lanes 4 and 8). The suppression of cisplatin-induced apop-
tosis by Bcl2L12 also was determined. Knockdown of Bcl2L12 did
not facilitate the activation of apoptotic markers in MCF-7–LacZ/
−ERβ5 (Figure 5A, lanes 6 and 12). However, down-regulation of
Bcl2L12 expression increased the level of cleaved caspase 9, cleaved
caspase 7, and cleaved caspase 3 but not cleaved PARP in MDA-
LacZ/−ERβ5 (Figure 5B, lanes 6 and 12). Next, FACS analysis was
performed to confirm the inhibitory role of Bcl2L12 in drug-induced
apoptosis. The percentage of apoptotic cells in both cell lines signifi-
cantly increased on the knockdown of Bcl2L12, followed by treatment
with doxorubicin or cisplatin (Figure 5, C and D). Consistent with the
results of Western blot analysis, ectopic expression of ERβ5, together
with Bcl2L12 depletion, resulted in the highest percentage of apop-
totic cells (Figure 5, C and D, lower right panel ). Our results not
only reveal that Bcl2L12 confers chemoresistance to doxorubicin- or
cisplatin-induced apoptosis in BCa cells but also imply that ERβ5
and Bcl2L12 play opposing roles in the apoptosis of BCa cells.
Figure 2. Ectopic ERβ5 sensitizes MCF-7 to doxorubicin-induced apoptosis. (A) ERβ5 and LacZ stably expressed MCF-7 (MCF-7–ERβ5
and MCF-7–LacZ) were treated with different concentrations of doxorubicin (0, 0.4, 2, and 10 μM) for 24 hours. Whole-cell lysates were
extracted for Western blot analysis with antibodies as indicated. Band intensities were measured and normalized to the intensity of
α-tubulin. The relative band intensities were compared with that of LacZ stably expressed cells without the treatment. Results of
densitometric analysis are the average of three measurements in a representative experiment. Data are presented as means ± SD.
The statistical significance of the difference in densitometric analysis between MCF-7–ERβ5 and MCF-7–LacZ at the same concentration
of doxorubicin is shown as *P < .05, **P < .01, and ***P < .001. (B) Annexin V/7-AAD staining assays were performed in ERβ5 (gray)
and LacZ (black) stably expressed MCF-7 cells. Cells were incubated with different concentrations of doxorubicin (0, 2, and 10 μM) for
18 hours. The percentage of annexin V–positive (apoptotic) cells was determined by FACS. Three independent experiments were per-
formed. The results shown are from a representative experiment. (C) Cell viability of MCF-7 stably expressed cell lines was measured by
MTS assay. Equal numbers of cells (3 × 103) were seeded on 96-well plates. Cells were incubated with 2 μM doxorubicin after 24 hours.
The data were recorded on the first and second days after drug treatment and represented as the percentage of cell viability relative
to that of untreated cells. Results are the average of three independent experiments; each was performed in triplicate. Data are repre-
sented as means ± SD. The statistical significance of the difference in cell viability between ERβ5 and LacZ stably expressed cells is
shown as *P < .05 and ***P < .001.
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ERβ5 Sequesters Bcl2L12 from Interacting with Caspase 7
In our current study, ERβ5 sensitized BCa cells to apoptosis induced
by chemotherapeutic agents, whereas Bcl2L12 inhibited the response
to treatment with different drugs. Because Bcl2L12 has been shown
to repress apoptosis in glioblastoma by preventing the cleavage of cas-
pase 7 through physical binding [34], we proposed that the interaction
between Bcl2L12 and caspase 7 also occurs in BCa and that it may be
inhibited by ERβ5. To understand how ERβ5-Bcl2L12 interaction reg-
ulates apoptosis in BCa cells, we performed co-IP of Bcl2L12 and cas-
pase 7 in MCF-7. On immunoprecipitation with antibody to Bcl2L12,
caspase 7 was coimmunoprecipitated in MCF-7–LacZ, whereas the
binding of caspase 7 to Bcl2L12 was drastically reduced in MCF-7–
ERβ5 (Figure 6). Because ERβ5 interacted with Bcl2L12 in MCF-7
(Figure 4B), our data suggest that ERβ5 inhibits the physical binding
between Bcl2L12 and caspase 7.
Discussion
ERβ5 has been shown to be positively correlated with survival out-
comes such as RFS and OS in patients with BCa [29,31], suggest-
ing that ERβ5 is a good prognostic marker in BCa. In our study,
Figure 4. Bcl2L12 specifically interacts with ERβ5 in an E2-independent manner. (A) ERβ5 interacts with Bcl2L12 in vivo in an E2-
independent manner. The 293T cells were grown in charcoal-stripped serum medium and transfected with ERβ5 and His-tagged Bcl2L12.
After 24-hour transfection, DMSO or 10 nM E2 was added. Lysates were immunoprecipitated with ERβ antibody and then immunoblotted
with His (Bcl2L12) or ERβ antibody. IgG was used as negative control. (B) ERβ5 interacts with Bcl2L12 in MCF-7. MCF-7–ERβ5 was grown in
full-serum medium. Lysates were immunoprecipitated with ERβ antibody and then immunoblotted with Bcl2L12 (L12-1) or ERβ antibody.
Figure 3. Ectopic ERβ5 sensitizes MCF-7 to cisplatin-induced apoptosis. (A) ERβ5 and LacZ stably expressed MCF-7 were treated with
different concentrations of cisplatin (0, 25, and 50 μM) for 24 hours. Whole-cell lysates were extracted for Western blot analysis with
antibodies as indicated. The measurement of relative band intensities and analysis of data were similar to those in Figure 2A. The statis-
tical significance of the difference in densitometric analysis between MCF-7–ERβ5 and MCF-7–LacZ at the same concentration of cisplatin
is shown as *P < .05, **P < .01, and ***P < .001. (B) Annexin V/7-AAD staining assays were performed in ERβ5 (gray) and LacZ
(black) stably expressed MCF-7 cells. Cells were incubated with different concentrations of cisplatin (0, 25, and 50 μM) for 18 hours. Other
experimental details and analysis of data were similar to those in Figure 2B. (C) The cell viability of MCF-7 stably expressed cell lines was
measured by MTS assay. Cells were incubated with 50 μM cisplatin. The procedures of experiment and analysis of data were similar to
those described in Figure 2C . The statistical significance of the difference in cell viability between ERβ5 and LacZ stably expressed cells
is shown as **P < .01.
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Figure 5. Knockdown of Bcl2L12 sensitizes MCF-7 and MDA-MB-231 to doxorubicin- and cisplatin-induced apoptosis. (A and B) ERβ5
and LacZ stably expressed MCF-7 (A) or MDA-MB-231 (B) were transfected with control siNT or Bcl2l12 siRNA (siL12-1) twice. The
cells were then treated with doxorubicin (2 μM) or cisplatin (50 μM) for 24 hours. Whole-cell lysates were extracted for Western blot
analysis with antibodies as indicated. The measurement of relative band intensities and analysis of data were similar to those in
Figure 2A. Cleavage of caspase 9 gives rise to a doublet band, which is indicated by arrows. The statistical significance of the difference
in densitometric analysis between the cells treated with siNT and siL12-1 at the same concentration of drugs is shown as *P < .05,
**P < .01, and ***P < .001. (C and D) Annexin V/7-AAD staining assays were performed. MCF-7–LacZ (C) or MDA-LacZ (D) transfected
with siNT (red) and siL12-1 (purple), as well as MCF-7–ERβ5 (C) or MDA-ERβ5 (D) transfected with siNT (green) or siL12-1 (blue) were
used in the assays. Cells were incubated with doxorubicin (2 μM) and cisplatin (50 μM) for 18 hours. Other experimental details and
analysis of data were similar to those in Figure 2B.
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expression of ERβ5, unlike that of ERβ1, had no effect on cell prolif-
eration. Nonetheless, ERβ5 decreased the cell survival by sensitizing
the BCa cell lines MCF-7 and MDA-MB-231 to doxorubicin- or
cisplatin-induced apoptosis. In contrast, Bcl2L12, which was isolated
as an ERβ5-specific interacting partner, conferred chemoresistance of
BCa cells to drug-induced apoptosis. We also showed that ERβ5 pre-
vented Bcl2L12 from interacting with caspase 7. Thus, ERβ5 is able
to sensitize BCa cells to chemotherapeutic agents through Bcl2L12.
Ectopic expression of ERβ5 sensitized the two BCa cell lines to
doxorubicin-induced apoptosis, as shown in Western blot analysis,
FACS analysis, and cell viability assays. In addition, on treatment
with cisplatin, ERβ5 enhanced apoptosis of MDA-MB-231, as well
as MCF-7, which is resistant to the drug [47–49]. Because MCF-7
and MDA-MB-231 possess wild-type and mutant p53, respectively,
our data indicate that the ERβ5-mediated apoptotic pathway is inde-
pendent of p53. Moreover, ERα status did not affect the sensitivity
of these cell lines to doxorubicin and cisplatin. Therefore, we sug-
gest that ERβ5-mediated sensitization for chemotherapeutic agent–
induced apoptosis is independent of its inhibition of ERα genomic
signaling but probably acts through a novel pathway involving the
interaction with an apoptotic protein, Bcl2L12.
We performed yeast two-hybrid screening to identify novel bind-
ing partners of ERβ5. One of the prey candidates, Bcl2L12, inter-
acted specifically with ERβ5 but not with ERβ1 or ERα in either
the absence or presence of E2. ERβ5 has the same N terminus
sequence as ERβ1 but a different C-terminal region [25]. The ob-
servation is not uncommon for ERs and their interacting proteins.
Physical binding between ERs and p160 coactivators requires syn-
ergy between N-terminal AF-1 and C-terminal AF-2 domains [50–
55]. Moreover, our three-dimensional molecular models showed that
the absence of helix 12 and the incomplete helix 11 of ERβ5 con-
stitute a conformation of the C terminus different from that of
ERβ1 [25]. Thus, the unique protein conformation of ERβ5 may
be responsible for its interaction with Bcl2L12. Collectively; the
data reveal that Bcl2L12 interacts specifically with ERβ5, but not
ERα or ERβ1, in an E2-independent manner. In addition, this
is the first discovery of an interaction between an ER and a Bcl-2
family member.
To determine the significance of the ERβ5-Bcl2L12 interaction
for apoptosis, we first clarified the function of Bcl2L12 in BCa cells.
Using two validated siRNAs [34], we showed that Bcl2L12 confers
chemoresistance of BCa cells to doxorubicin or cisplatin. Moreover,
ectopic expression of ERβ5 with Bcl2L12 depletion resulted in
the highest degree of apoptosis in the two cell lines, as reflected in
Western blot and FACS analyses. Although Bcl2L12 depletion
followed by cisplatin treatment of MCF-7 dramatically increased
apoptosis in FACS analysis, expression of apoptotic markers did not
show a change in Western blot analysis. The discrepancy between
the results of the two experiments may be due to differences in the
apoptotic markers used in FACS (cell-surfaced phosphatidylserine)
and Western blot (cleaved form of different caspases and PARP) analy-
ses. Bcl2L12 plays distinct roles in the apoptosis of different cancers.
It is antiapoptotic in glioblastoma [33,56,57] but promoted cisplatin-
induced apoptosis in MDA-MB-231 in one study [58]. In our cur-
rent study, similar to the studies of glioblastoma, we showed that
Bcl2L12 inhibits apoptosis. The difference between the findings of
our current study and that of a previous study in BCa [58] could
be explained in several ways. In our study, the function of Bcl2L12
on doxorubicin- and cisplatin-triggered apoptosis was determined in
MCF-7 and MDA-MB-231. Moreover, we do not believe that off-
target effects are present because both Stegh et al. [34] and our group
(Figure W4, D–G ) validated two separate siRNAs. In addition, dif-
ferent passage numbers of cells and the use of different culture con-
ditions may lead to differential cellular responses. Here, we conclude
that Bcl2L12 confers chemoresistance of BCa cells to doxorubicin or
cisplatin, whereas ectopic expression of ERβ5 with Bcl2L12 depletion
further enhances the apoptosis.
In the presence of chemotherapeutic agents, ERβ5 promoted apop-
tosis, which was augmented when expression of Bcl2L12 was knocked
down, implying that Bcl2L12 inhibits the ERβ5-mediated apoptotic
pathway. Suppression of apoptotic signaling by Bcl2L12 has been
studied extensively in glioblastoma [34,57,59,60] and found to inhibit
the activity of caspase 7 through physical binding [34]. Our study
showed that the interaction between Bcl2L12 and caspase 7 is reduced
in the presence of ERβ5. This suggests that Bcl2L12 can no longer
repress the cleavage of caspase 7 when ERβ5 is expressed, resulting
in a mechanism by which ERβ5 sensitizes cells to apoptosis. How-
ever, we also observed an increase in the activation of caspase 9 in
ERβ5-expressing BCa cells compared with the controls treated with
same concentration of drugs (Figures 2A and 3A; Figures W1A and
W2A). Because caspase 9 functions at an early stage of the intrinsic
apoptotic pathway [61], ERβ5 may have additional mechanism(s) of
enhancing apoptosis.
In conclusion, our study revealed a novel estrogen-independent
molecular pathway of ERβ5 in BCa cells. To our knowledge, we
are the first to illustrate that ERβ5 confers sensitivity of BCa cells to
chemotherapeutic agent–induced apoptosis through the intrinsic
pathway. Moreover, we discovered the estrogen-independent ERβ5-
Bcl2l12 interaction and uncovered the ERβ5-mediated sensitization
stem from its inhibition of Bcl2L12–caspase 7 interaction. Our fur-
ther research will focus on the functions of ERβ5 and Bcl2L12 in vivo
and their prognostic values in BCa. Because the ERβ5-mediated sen-
sitization occurred in BCa cell lines with different statuses of ERα
and p53, ERβ5 may be a new therapeutic target for various types of
BCa. Moreover, our study yields valuable information concerning
the development of small molecules or peptide mimics targeting
the ERβ5-Bcl2L12 interaction to enhance the efficacy of chemo-
therapeutic agents for patients with advanced BCa.
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Figure 6. ERβ5 inhibits the interaction between Bcl2L12 and
caspase 7. ERβ5 and LacZ stably expressed MCF-7 cells were
grown in full-serum medium. Lysates were immunoprecipitated
with Bcl2L12 (L12-2) antibody and then immunoblotted with cas-
pase 7 or Bcl2L12 (L12-1) antibody. IgGwas used as negative control.
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Figure W1. Ectopic ERβ5 sensitizes MDA-MB-231 to doxorubicin-induced apoptosis. (A) ERβ5 and LacZ stably expressed MDA-MB-231
(MDA-ERβ5 and MDA-LacZ) were treated with different concentrations of doxorubicin (0, 5, and 10 μM) for 24 hours. Whole-cell lysates
were extracted for Western blot analysis with antibodies as indicated. Band intensities were measured and normalized to the intensity of
α-tubulin. The relative band intensities were compared with that of untreated LacZ stably expressed cells. Results are the average of three
measurements in a representative experiment. Data are presented as means ± SD. Similar results were obtained in cells incubated with
doxorubicin for 12 hours. The statistical significance of the difference in densitometric analysis between MDA-ERβ5 and MDA-LacZ at
the same concentration of doxorubicin is shown as *P < .05, **P < .01, and ***P < .001. (B) Annexin V/7-AAD staining assays were
performed in ERβ5 (green) and LacZ (red) stably expressed MDA-MB-231 cells. Cells were incubated with different concentrations of
doxorubicin (0, 5, and 10 μM) for 18 hours. The percentage of annexin V–positive (apoptotic) cells was determined by FACS. Three
independent experiments were performed. The results shown are from a representative experiment. (C) The cell viability of MDA-MB-
231 stably expressed cell lines was measured by MTS assay. Equal numbers of cells (3 × 103) were seeded on 96-well plates. Cells were
incubated with 5 μMdoxorubicin after 24 hours. The data were recorded on the first and second days after drug treatment and represented
as the percentage of cell viability relative to that of untreated cells. The results are the average of three independent experiments; each was
performed in triplicate. Data are represented as means ± SD. The statistical significance of the difference in cell viability between ERβ5 and
LacZ stably expressed cells is shown as *P < .05.
Figure W2. Ectopic ERβ5 sensitizes MDA-MB-231 to cisplatin-induced apoptosis. (A) ERβ5 and LacZ stably expressed MDA-MB-231 were
treated with different concentrations of cisplatin (0, 25, and 50 μM) for 24 hours. Whole-cell lysates were extracted for Western blot analy-
sis with antibodies as indicated. The measurement of relative band intensities and analysis of data were similar to those in Figure W1A. The
statistical significance of the difference in densitometric analysis betweenMDA-ERβ5 andMDA-LacZ at the same concentration of cisplatin
is shown as *P < .05, **P < .01, and ***P < .001. (B) Annexin V/7-AAD staining assays were performed in ERβ5 (green) and LacZ (red)
stably expressed MDA-MB-231 cells. Cells were incubated with different concentrations of cisplatin (0, 25, and 50 μM) for 18 hours. Other
experimental details and analysis of data were similar to those in FigureW1B. (C) The cell viability ofMDA-MB-231 stably expressed cell lines
was measured byMTS assay. Cells were incubated with 50 μMcisplatin. The procedures of experiment and analysis of data were similar to
those described in Figure W1C . The statistical significance of the difference in cell viability between ERβ5 and LacZ stably expressed cells
is shown as **P < .01.
Figure W3. Bcl2L12 specifically interacts with ERβ5 but not ERβ1 or ERα. (A) Full-length ERβ5 and ERα, but not ERβ1, interact with Bcl2L12
in yeast. ERβ1, ERβ5, ERα, or empty vector (pGBKT7) was transformed with Bcl2L12 into yeast cells. Transformed cells were seeded on
QDO containing X-α-galactosidase until growth of blue colonies. (B) Bcl2L12 interacts with ERβ5 but not ERβ1 or ERα in vitro. ERβ5, ERβ1,
ERα, and HA-tagged Bcl2L12, respectively, were translated in vitro and labeled with [35S] methionine. Lysates were mixed and incubated
in the absence or presence of E2 as indicated, followed by immunoprecipitation with anti-HA affinity gel. The immunoprecipitates were
resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and analyzed by X-ray autoradiography. The asterisk (*), number
sign (#), and plus sign (+) respectively indicate the positions of ERβ5, ERα, and ERβ1. (C and D) ERβ5 colocalized with Bcl2L12 in 293T and
MCF-7–ERβ5 cells. The two cell lines were grown in full-serummedium. The 293T cells were transfectedwith ERβ5 and Bcl2L12. Antibodies
to ERβ and Bcl2L12 were used for immunostaining. DAPI was used as a nuclear marker. Images in C and D were captured by fluorescence
microscopy. Bar = 20 μm.
Figure W4. Expression of Bcl2L12 was significantly reduced by gene-specific siRNAs in MCF-7 and MDA-MB-231. (A) Expression level
of Bcl2L12 in different mammary cell lines was determined. The cDNAs of BCa cell lines (MDA-MB-231, MCF-7, T47D, and SKBR-3) and
mammary epithelial cells (MCF-10A) were used in quantitative RT-PCR. The results are the average of two independent experiments.
(B and C) Expression of Bcl2L12 is not altered by the ectopic expression of ERβ5 in BCa cells. The cDNAs of MCF-7–ERβ5/−LacZ (B)
and MDA-ERβ5/−LacZ (C) were used in quantitative RT-PCR. The results are the average of two independent experiments. (D–G) Bcl2L12
siRNAs efficiently reduced its expression in MCF-7 and MDA-MB-231. Two Bcl2L12-specific siRNAs (siL12-1 and siL12-2) were transfected
into MCF-7 (D and E) and MDA-MB-231 (F and G). After 24-hour transfection, cells were transfected for the second time. siNT was used
as negative control. The relative expression of Bcl2L12 was measured by quantitative RT-PCR and Western blot analysis. β-Actin was used
as loading control in Western blot analysis. The results of quantitative RT-PCR are the average of three independent experiments. All data
are represented as means ± SD. (H and I) ERβ5 and Bcl2L12 expression in MCF-7–ERβ5/−LacZ and MDA-ERβ5/−LacZ cells with or
without Bcl2L12 siRNA knockdown.
Figure W5. Knockdown of Bcl2L12 by siL12-2 sensitizes doxorubicin-induced apoptosis in MCF-7 and MDA-MB-231. (A and B) siNT or
siL12-2 was transfected twice into MCF-7–ERβ5/−LacZ (A) and MDA-ERβ5/−LacZ (B). MCF-7 cells were incubated with 2 μM doxorubicin,
and MDA-MB-231 cells were incubated with 5 μM doxorubicin. Whole-cell lysates were extracted for Western blot analysis with antibodies
as indicated. The measurement of relative band intensities and analysis of data were similar to those in Figure W1A. The statistical signifi-
cance of the difference in densitometric analysis between the cells treated with siNT and siL12-1 at the same concentration of doxorubicin
is shown as *P < .05, **P < .01, and ***P < .001.
